Lumacaftor and Ivacaftor use while Breastfeeding
Medically reviewed by Drugs.com. Last updated on March 5, 2021.
Lumacaftor and Ivacaftor Levels and Effects while Breastfeeding
Summary of Use during Lactation
Information from one maternal-infant pair with ivacaftor and lumacaftor indicates that maternal ivacaftor therapy produce low levels in milk. An international survey of cystic fibrosis centers found no adverse effects in breastfed infants of mothers taking these drugs. A task force respiratory experts from Europe, Australia and New Zealand found that these drugs are probably safe during breastfeeding. One breastfed infant had transient elevations in bilirubin and liver enzymes during maternal therapy that could not definitively be attributed to the drugs in breastmilk. Until more data are available, monitoring of infant bilirubin and liver enzymes might be advisable during breastfeeding with maternal lumacaftor and ivacaftor therapy. Examination of breastfed infants for cataracts has also been recommended.
Maternal Levels. A woman with cystic fibrosis was treated with lumacaftor and ivacaftor during pregnancy and postpartum. The dosage was not stated, but it was probably the standard dosage of lumacaftor 400 mg and ivacaftor 250 mg orally every 12 hours. The average concentrations in breastmilk samples taken randomly over a 6-month period without regard to the times of the doses were lumacaftor 27.4 mcg/L (0.06 micromolar) and ivacaftor 35.3 mcg/L (0.09 micromolar).
Infant Levels. An infant was breastfed by a mother taking lumacaftor and ivacaftor. The percentage of breastfeeding varied between 25% and 100% during this time period. Average infant plasma concentrations over the first 6 months of life, excluding day 1 postpartum, were lumacaftor 90.5 mcg/L (0.20 micromolar) and ivacaftor 3.9 mcg/L (0.01 micromolar), respectively. These values corresponded to averages of 2.7% and 0.5%, respectively, of simultaneous maternal plasma levels.
Effects in Breastfed Infants
A woman with cystic fibrosis was treated with lumacaftor and ivacaftor during pregnancy and postpartum. Her infant was fully breastfed until day 29 postpartum when elevated direct and indirect bilirubin, aspartate aminotransferase (AST), and alkaline phosphatase were found to be elevated. All values had been normal on days 1 and 14. The fraction of breastmilk the infant received was reduced to 25% and all values were normal on day 37. The fraction of breastfeeding was increased to 50% and then to 100%. On day 135, the infant's direct bilirubin was elevated during concurrent maternal levofloxacin and trimethoprim-sulfamethoxazole therapy. The fraction of breastfeeding was decreased to 75% and the direct bilirubin was normal on day 154. The authors noted that the abnormal test results could not definitively be attributed to lumacaftor and ivacaftor therapy. The elevation in liver enzymes was possibly caused by lumacaftor and ivacaftor in breastmilk.
A survey was sent to lead clinicians of adult CF centers in Europe, the United Kingdom, United States of America, Australia and Israel requesting anonymized data on pregnancy outcomes in women using CFTR modulators during pregnancy and lactation. Responses were received from 31 centers and one woman with CF for a total of 64 pregnancies in 61 women resulting in 60 live births. Thirteen infants were breastfed on ivacaftor alone, 9 infants were breastfed on lumacaftor and ivacaftor, and 5 infants were breastfed on tezacaftor and ivacaftor for a total of 27 infants exposed to ivacaftor in breastmilk, all with no reported complications. The extent of breastfeeding was not reported.
An updated survey by the same authors asked CF clinicians to report on pregnant women exposed to the elexacaftor, tezacaftor and ivacaftor combination during pregnancy and breastfeeding. Twenty-six infants were breastfed (extent not stated) during maternal use of the combination. No adverse effects were reported in the breastfed infants.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55:1901208. [PubMed: 31699837]
Jain R, Taylor-Cousar JL. Fertility, pregnancy and lactation considerations for women with CF in the CFTR modulator era. J Pers Med. 2021;11:418. [PMC free article: PMC8156060] [PubMed: 34063507]
Taylor-Cousar JL. CFTR modulators: Impact on fertility, pregnancy, and lactation in women with cystic fibrosis. J Clin Med. 2020;9:2706. [PMC free article: PMC7563981] [PubMed: 32825766]
Trimble A, McKinzie C, Terrell M, et al. Measured fetal and neonatal exposure to lumacaftor and ivacaftor during pregnancy and while breastfeeding. J Cyst Fibros. 2018;17:779–82. [PMC free article: PMC6354249] [PubMed: 29866531]
Nash EF, Middleton PG, Taylor-Cousar JL. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey. J Cyst Fibros. 2020;19:521–6. [PubMed: 32151568]
Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros. 2021;20:402–6. [PubMed: 33762125]
Lumacaftor and Ivacaftor
CAS Registry Number
1815566-23-4 936727-05-8 873054-44-5
Chloride Channel Agonists
Cystic Fibrosis Transmembrane Conductance Regulator Protein Modulator
CFTR Protein Modulator
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.